Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nifuratel→

Nifuratel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
4936-47-4
Molecular formula
C10H11N3O5S
Molecular weight
285.28 g/mol
Drug class
Nitrofuran antimicrobiallocal antiprotozoal, antifungal and antibacterial agent
Mechanism of action
A nitrofuran anti-infective with activity against selected bacteria, protozoa and fungi. The precise molecular mechanism is not fully established; nitrofuran compounds can undergo microbial reduction to reactive intermediates that interfere with essential microbial enzymes and cellular processes.
Indications / reported uses
  • Local treatment of vulvovaginal infections involving susceptible bacteria, Trichomonas and Candida species in authorised formulations.
  • Oral use for selected gastrointestinal or urinary infections is product- and jurisdiction-specific.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=nifuratel · https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?ligandId=12348&tab=clinical · https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?ligandId=12348&tab=summary · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nifuratel Environmental Risk Assessment (ERA) (the Nifuratel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.